Alison Birtle, MRCP, FRCR, MD, Lancashire Teaching Hospitals, Preston, UK, shares her highlights from ASCO GU 2021, in particular discussing the promising results seen with studies of the antibody-drug conjugate enfortumab vedotin, oral docetaxel and 177Lu-PSMA-617 versus cabazitaxel. This interview took place during the 2021 Genitourinary Cancers Symposium.

свернуть